Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$18.18 USD
+0.20 (1.11%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $18.17 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
Income Statements
Fiscal Year end for Myriad Genetics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 753 | 678 | 691 | 155 | 639 |
Cost Of Goods | 236 | 202 | 198 | 47 | 186 |
Gross Profit | 517 | 476 | 493 | 108 | 453 |
Selling & Adminstrative & Depr. & Amort Expenses | 774 | 617 | 684 | 255 | 684 |
Income After Depreciation & Amortization | -257 | -141 | -191 | -148 | -232 |
Non-Operating Income | -2 | 3 | 140 | -5 | 19 |
Interest Expense | 3 | 3 | 7 | 3 | 11 |
Pretax Income | -262 | -141 | -57 | -56 | -223 |
Income Taxes | 1 | -29 | -30 | -12 | -24 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -263 | -112 | -27 | -44 | -200 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -263 | -112 | -27 | -44 | -200 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -196 | -71 | -126 | -112 | -160 |
Depreciation & Amortization (Cash Flow) | 62 | 70 | 65 | 36 | 72 |
Income After Depreciation & Amortization | -257 | -141 | -191 | -148 | -232 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 82.80 | 80.60 | 78.00 | 74.30 | 76.00 |
Diluted EPS Before Non-Recurring Items | -0.76 | -0.67 | -0.35 | -0.35 | 1.29 |
Diluted Net EPS (GAAP) | -3.18 | -1.39 | -0.35 | -2.69 | -2.69 |
Fiscal Year end for Myriad Genetics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 196.60 | 191.90 | 183.50 | 181.20 |
Cost Of Goods | NA | 61.60 | 57.60 | 57.80 | 59.20 |
Gross Profit | NA | 135.00 | 134.30 | 125.70 | 122.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 166.40 | 194.40 | 239.40 | 174.20 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -31.40 | -60.10 | -113.70 | -52.20 |
Non-Operating Income | NA | 0.00 | -0.10 | -1.90 | 0.10 |
Interest Expense | NA | 0.90 | 1.00 | 0.50 | 0.50 |
Pretax Income | NA | -32.30 | -61.20 | -116.10 | -52.60 |
Income Taxes | NA | -1.10 | 0.10 | 0.00 | 2.10 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -31.20 | -61.30 | -116.10 | -54.70 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -31.20 | -61.30 | -116.10 | -54.70 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 86.10 | 81.90 | 81.70 | 81.30 |
Diluted EPS Before Non-Recurring Items | NA | -0.07 | -0.17 | -0.21 | -0.28 |
Diluted Net EPS (GAAP) | NA | -0.34 | -0.75 | -1.42 | -0.67 |